Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report

RATIONALE: Lung cancer is the cancer with the highest incidence and mortality in China and worldwide. Among them, 85% are non-small cell lung cancer (NSCLC). No previous reports have been published to describe the clinical effect of the immune checkpoint inhibitor (ICI) sintilimab in NSCLC yet. PATI...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lin, Mai, Wuqian, Hao, Bo, Jiang, Wenyang, Geng, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
6700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249863/
https://www.ncbi.nlm.nih.gov/pubmed/32481252
http://dx.doi.org/10.1097/MD.0000000000019790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249863/
https://www.ncbi.nlm.nih.gov/pubmed/32481252
http://dx.doi.org/10.1097/MD.0000000000019790

Ejemplares similares